Thaci 2010.

Methods	This was a randomised, vehicle‐controlled trial, which lasted 16 weeks. Participants were treated in the phase IIIb, multicentre European study BELIEVE.
Participants	Inclusion criteria of the trial BELIEVE study: Participants with moderate to severe psoriasis who had failed, been intolerant of, or had contraindications to more than 2 systemic therapies
Interventions	Adalimumab 80 mg at week 0, and 40 mg every other week from weeks 1 to 15 Either topical vehicle or topical calcipotriol/betamethasone (C/B) (once daily for 4 weeks, and thereafter as needed (PRN: pro re nata); face, scalp, and nails excluded).
Outcomes	Outcomes of the trial Nails were assessed by NAPSI of the hands (range = 0 to 80) at baseline, week 8, and week 16.
Notes	This was a poster presentation.